Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium

Patricia K. Sonsalla, Gail D. Zeevalk, Dwight C. German

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter introduces two models of Parkinson's disease (PD), and discuses their utility in the examination of impaired energy metabolism on DA homeostasis and for pharmacological testing of potential neuroprotective compounds. One of models presented is created by a chronic, continuous low dose administration of MPP+ into the cerebral ventricle. The other model results from a single acute administration of MPP+ or malonate into the striatum. The choice of which model to use depends on the research question. The chronic MPP+ model is progressive in nature, presents with neuropathology seen in PD brain, exhibits low inter-animal variability, no mortality, and because of the unilateral lesion, the animals are essentially healthy. While the model requires further characterization, it nonetheless has demonstrated its utility for pharmacological testing of neuroprotective agents. Moreover, because of the progressive nature of degeneration in the model, it can be used for testing therapeutic approaches targeted at the many cellular processes involved in degeneration. The single acute MPP+ or malonate PD model has proven to be especially beneficial when coupled with other injection formats or microdialysis to examine dynamic changes in brain regions subjected to a metabolic stress.

Original languageEnglish (US)
Title of host publicationParkinson's Disease
PublisherElsevier Inc.
Pages159-172
Number of pages14
ISBN (Print)9780123740281
DOIs
StatePublished - 2008

Fingerprint

1-Methyl-4-phenylpyridinium
Parkinson Disease
Pharmacology
Cerebral Ventricles
Physiological Stress
Microdialysis
Brain
Neuroprotective Agents
Energy Metabolism
Homeostasis
Injections
Mortality
Research
malonic acid
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sonsalla, P. K., Zeevalk, G. D., & German, D. C. (2008). Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium. In Parkinson's Disease (pp. 159-172). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374028-1.00012-9

Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium. / Sonsalla, Patricia K.; Zeevalk, Gail D.; German, Dwight C.

Parkinson's Disease. Elsevier Inc., 2008. p. 159-172.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sonsalla, PK, Zeevalk, GD & German, DC 2008, Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium. in Parkinson's Disease. Elsevier Inc., pp. 159-172. https://doi.org/10.1016/B978-0-12-374028-1.00012-9
Sonsalla, Patricia K. ; Zeevalk, Gail D. ; German, Dwight C. / Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium. Parkinson's Disease. Elsevier Inc., 2008. pp. 159-172
@inbook{3b9117abb8964121acd1c2681f4cd22d,
title = "Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium",
abstract = "This chapter introduces two models of Parkinson's disease (PD), and discuses their utility in the examination of impaired energy metabolism on DA homeostasis and for pharmacological testing of potential neuroprotective compounds. One of models presented is created by a chronic, continuous low dose administration of MPP+ into the cerebral ventricle. The other model results from a single acute administration of MPP+ or malonate into the striatum. The choice of which model to use depends on the research question. The chronic MPP+ model is progressive in nature, presents with neuropathology seen in PD brain, exhibits low inter-animal variability, no mortality, and because of the unilateral lesion, the animals are essentially healthy. While the model requires further characterization, it nonetheless has demonstrated its utility for pharmacological testing of neuroprotective agents. Moreover, because of the progressive nature of degeneration in the model, it can be used for testing therapeutic approaches targeted at the many cellular processes involved in degeneration. The single acute MPP+ or malonate PD model has proven to be especially beneficial when coupled with other injection formats or microdialysis to examine dynamic changes in brain regions subjected to a metabolic stress.",
author = "Sonsalla, {Patricia K.} and Zeevalk, {Gail D.} and German, {Dwight C.}",
year = "2008",
doi = "10.1016/B978-0-12-374028-1.00012-9",
language = "English (US)",
isbn = "9780123740281",
pages = "159--172",
booktitle = "Parkinson's Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium

AU - Sonsalla, Patricia K.

AU - Zeevalk, Gail D.

AU - German, Dwight C.

PY - 2008

Y1 - 2008

N2 - This chapter introduces two models of Parkinson's disease (PD), and discuses their utility in the examination of impaired energy metabolism on DA homeostasis and for pharmacological testing of potential neuroprotective compounds. One of models presented is created by a chronic, continuous low dose administration of MPP+ into the cerebral ventricle. The other model results from a single acute administration of MPP+ or malonate into the striatum. The choice of which model to use depends on the research question. The chronic MPP+ model is progressive in nature, presents with neuropathology seen in PD brain, exhibits low inter-animal variability, no mortality, and because of the unilateral lesion, the animals are essentially healthy. While the model requires further characterization, it nonetheless has demonstrated its utility for pharmacological testing of neuroprotective agents. Moreover, because of the progressive nature of degeneration in the model, it can be used for testing therapeutic approaches targeted at the many cellular processes involved in degeneration. The single acute MPP+ or malonate PD model has proven to be especially beneficial when coupled with other injection formats or microdialysis to examine dynamic changes in brain regions subjected to a metabolic stress.

AB - This chapter introduces two models of Parkinson's disease (PD), and discuses their utility in the examination of impaired energy metabolism on DA homeostasis and for pharmacological testing of potential neuroprotective compounds. One of models presented is created by a chronic, continuous low dose administration of MPP+ into the cerebral ventricle. The other model results from a single acute administration of MPP+ or malonate into the striatum. The choice of which model to use depends on the research question. The chronic MPP+ model is progressive in nature, presents with neuropathology seen in PD brain, exhibits low inter-animal variability, no mortality, and because of the unilateral lesion, the animals are essentially healthy. While the model requires further characterization, it nonetheless has demonstrated its utility for pharmacological testing of neuroprotective agents. Moreover, because of the progressive nature of degeneration in the model, it can be used for testing therapeutic approaches targeted at the many cellular processes involved in degeneration. The single acute MPP+ or malonate PD model has proven to be especially beneficial when coupled with other injection formats or microdialysis to examine dynamic changes in brain regions subjected to a metabolic stress.

UR - http://www.scopus.com/inward/record.url?scp=84882531869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882531869&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374028-1.00012-9

DO - 10.1016/B978-0-12-374028-1.00012-9

M3 - Chapter

AN - SCOPUS:84882531869

SN - 9780123740281

SP - 159

EP - 172

BT - Parkinson's Disease

PB - Elsevier Inc.

ER -